University of Bristol Bristol Medical School Supervisors: Dr Gibran Hemani, Prof Simon Satchell, Dr Venexia Walker, Dr Samantha Hayward Application
deadline: Sunday, December 13, 2026 Funding: Competition Funded PhD Project (Students Worldwide) About the Project Chronic kidney disease (CKD) is a leading global health crisis, with the vast majority of excess deaths driven by cardiovascular disease (CVD). Recent large-scale epidemiological studies demonstrate that kidney function measures based on cystatin C (eGFR_cys) are significantly stronger predictors of CVD and mortality than traditional creatinine-based measures (eGFR_cr). The ratio of eGFR_cys to eGFR_cr defines Selective Glomerular Hypofiltration Syndrome (SGHS)—a condition characterized by a relative reduction in cystatin C clearance due to altered glomerular filtration barrier (GFB) properties, specifically small-pore ("shrunken pore syndrome") dysfunction linked to endothelial glycocalyx (eGlx) damage. However, whether SGHS is a direct causal driver of CVD or merely a biomarker proxy for generalized eGlx dysfunction remains a major unsolved question in cardiovascular medicine. This PhD project will harness massive-scale genetic epidemiology and causal inference methodologies to determine the causal architecture linking SGHS, endothelial glycocalyx properties, and cardiovascular disease endpoints. Working jointly within the MRC Integrative Epidemiology Unit (IEU)—a world leader in Mendelian Randomization—and Bristol Renal the student will analyze population-level genomic data from UK Biobank (>500,000 participants) and the Avon Longitudinal Study of Parents and Children (ALSPAC). Aims and objectives To interrogate the genetic architecture of SGHS (eGFR_cys/eGFR_cr ratio) and endothelial glycocalyx depth via genome-wide association studies (GWAS) and Exome-Wide Association Studies (ExWAS). To apply Genomic Structural Equation Modelling (Genomic SEM) and multivariable/network Mendelian Randomization (MR) to establish causal pathways linking SGHS, structural eGlx depth, and cardiovascular endpoints (e.g., heart failure, myocardial infarction, angina). To perform proteomic mediation analyses and MR-PheWAS in UK Biobank and ALSPAC to identify downstream inflammatory and circulating protein mediators of SGHS, prioritizing genetic targets for downstream functional validation. Methods The student will utilize high-performance computing clusters at the MRC IEU to analyze existing genome-wide summary statistics and individual-level biobank data. Key methodological approaches include: Instrumental Variable Generation & GWAS/ExWAS: Identifying robust genetic variants associated with the eGFR_cys/eGFR_cr ratio and sublingual eGlx depth across UK Biobank and ALSPAC. Genomic SEM: Decomposing shared genetic architecture and pleiotropy between renal filtration traits and vascular phenotypes into conditionally independent biological modules. Multivariable & Network MR: Disentangling biomarker non-renal clearance from intrinsic glomerular pore dysfunction, rigorously controlling for pleiotropy and confounding to establish causal relationships with cardiovascular disease. Proteomic Mediation & MR-PheWAS: Interrogating plasma proteomic datasets (Olink in UK Biobank) to map causal links between genetic instruments for SGHS and downstream clinical disease traits across the human phenome. How to apply Before applying, please check the entry requirements . Submit your application via the University of Bristol portal . Search for and then select ‘Population Health Sciences (PhD)’. Click ‘Apply’ for September 2027 start. You must provide the following in your application: A CV Two referees (add to the Reference section of your application form) A personal statement highlighting your motivation for applying for this PhD, and any relevant experience and/or skills (maximum of one side of A4, font size 11). We are keen to support applicants from minority and under-represented backgrounds (based on protected characteristics ) and those who have experienced other challenges or disadvantages. Please use your personal statement to ensure we can take these factors into account. Certificates and transcripts Enter the project title and the supervisor names as they appear on this advert in the Research section. A research statement/proposal is not required. You should upload a blank document in this section. In the funding section, choose ‘University of Bristol Scholarship’. Incomplete applications will not be considered . Read the list above carefully and ensure you have uploaded all required documents by the deadline. If you have yet to complete your degree, please supply an interim transcript where possible. You can find more information on how to prepare your application and what we are looking for at the “PhD Application Workshop” which will be held on Teams on Monday 23rd November at 2pm (GMT): PhD Application Workshop . Applications will be shortlisted in January 2027 with interviews in February 2027. The anticipated start date for this scholarship is September 2027. Please visit our website for more information on PhD opportunities in the Faculty of Health and Life Sciences. Funding Notes This is a four-year scholarship covering tuition fees, a UKRI-rate stipend (£21,805 in 2026/27, updated annually), and £2,100 annual research costs. The scholarship is available to UK and International applicants. International candidates (including EU) will be required to cover the cost of their student visa, healthcare surcharge and other costs of moving to the UK. Further enquiries Research Group Website Project-specific queries: g.hemani@bristol.ac.uk Application queries: uob-pgradmissions@bristol.ac.uk References https://doi.org/10.1038/s41591-019-0627-8 https://doi.org/10.1080/00365513.2025.2546320 https://doi.org/10.1093/ndt/gfad145


